ArticleThe Journal of physiology2026
In silico predictions of action potential propagation in doxorubicin cardiotoxicity: A parametric study using preclinical 3D magnetic resonance imaging-based fibrotic left ventricle models.
Article in The Journal of physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiac digital twins: Modelling the arrhythmic substrate of chemotherapy.The Journal of physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Doxorubicin (DOX) is a widely used chemotherapeutic agent, but its cardiotoxic effects, including diffuse myocardial fibrosis, increase the risk of dangerous arrhythmias. There is a critical need for non-invasive tools to predict DOX-related ventricular arrhythmias in early chronic stages following chemotherapy. A computational study was performed using experimental data from three pigs: one control and two at 9 weeks following DOX. Customized 3D left ventricular (LV) models were generated from late gadolinium-enhanced magnetic resonance imaging and electro-anatomical maps, integrating tissue structure, electrical properties (healthy/fibrosis) and fibre directions. Action potential (AP) wave propagation was simulated using a high-performance numerical solver. A virtual programmed stimulation protocol was applied in 96 simulations to assess arrhythmia inducibility, varying the parameters corresponding to excitability and conduction velocity in fibrotic zones. Arrhythmias were inducible only in DOX-treated cases. Reentrant wave genesis depended on: excitability, conduction velocity, fibrosis distribution and AP duration heterogeneity. In one scenario, AP heterogeneities and a ≥70% reduction in diffusion coefficient were required to induce reentry despite unchanged excitability in fibrosis. This study presents the first computational simulation of DOX-induced cardiotoxicity in a realistic 3D LV model using a highly efficient, automated Lattice-Boltzmann approach. Our findings provide insights into arrhythmogenic mechanisms and may aid in developing strategies to prevent and treat DOX-related cardiotoxicity. KEY POINTS: We developed a novel semi-automated computational framework to construct high-resolution 3D magnetic resonance imaging-based left ventricular models designed to study via simulations the electrical activity after chemotherapy using a GPU-optimized Lattice-Boltzmann method solver. Our digital heart twins were directly calibrated and validated using measurements of conduction velocity and action potential wave features obtained via catheter-based electro-anatomical mapping after chemotherapy in preclinical swine models. This specific virtual parametric study demonstrates that both electrophysiological and structural alterations induced by diffuse fibrosis substantially modulate ventricular arrhythmias in the sub-chronic phase following doxorubicin therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.